Opzelura (ruxolitinib cream) / Incyte, Maruho, China Medical System - LARVOL DELTA

Efficacy and safety of oral upadacitinib-topical ruxolitinib combination therapy in the treatment of progressive nonsegmental vitiligo. (PubMed, JAAD Int) - No abstract available

Journal • Dermatology • Immunology • Vitiligo

Incyte Reports 2025 Second Quarter Financial Results... (Businesswire) - "Net product revenues for the second quarter 2025 of $164 million (+35% Y/Y): U.S. net product revenue of $132 million in the second quarter of 2025 increased 19% compared to the second quarter of 2024 driven by increased patient demand and refills in both atopic dermatitis (AD) and vitiligo. Opzelura inventory levels were within normal range at the end of the second quarter of 2025; Ex-U.S. net product revenues of $32 million in the second quarter of 2025 were primarily driven by continued growth in sales in France, and the recent launches in Italy and Spain....Niktimvo net product revenue reflects continued strong uptake of the product following its commercial launch during the first quarter of 2025."

Sales • Atopic Dermatitis • Chronic Graft versus Host Disease • Immunology • Vitiligo

Descriptive Analysis of Reported Adverse Events Associated with Vitiligo Medications Using FDA Adverse Event Reporting System (FAERS) Databases 2013-2023. (PubMed, Diseases) - "In 2022, the FDA approved Ruxolitinib cream, targeting the JAK/STAT pathway for NSV treatment based on promising results. This research conducts a retrospective descriptive safety assessment of Tacrolimus, Pimecrolimus, and Ruxolitinib safety in vitiligo treatment, utilizing the FDA Adverse Event Reporting System (FAERS) database spanning the period from 2013 to 2023 and including patients aged 2 years and above, encompassing both brand and generic names...Local dermatological side effects reported were generally mild, not warranting treatment cessation. In conclusion, vitiligo significantly impacts patients' psychological well-being, necessitating continuous post-marketing safety monitoring for topical medications."

Adverse events • Journal • Review • Cardiovascular • Dermatology • Hematological Disorders • Immunology • Musculoskeletal Diseases • Orthopedics • Pain • Urticaria • Vitiligo

Ionic Liquid-Mediated Delivery of Ruxolitinib to Skin Using an Adhesive Topical Hydrogel System. (PubMed, Adv Healthc Mater) - "Importantly, the IL-mediated transport of drug into the skin causes a significant increase in ruxolitinib accumulation within the dermis, surpassing that of a clinical ointment analog. By combining efficient skin permeation, controlled release, and strong adhesion, this multifunctional platform offers significant potential for topical drug delivery across a range of skin disorders, extending beyond atopic dermatitis."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis (clinicaltrials.gov) - P2 | N=15 | Recruiting | Sponsor: The Cleveland Clinic | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatomyositis • Immunology • Myositis

Management of Hailey-Hailey Disease with ruxolitinib 1.5% cream (EADV 2025) - No abstract available

Genetic Disorders

Enhancing Topical Ruxolitinib with Microneedling-Based Therapies: A Multimodal Approach for Progressive Vitiligo Repigmentation – A Case Series (EADV 2025) - No abstract available

Clinical • Dermatology • Immunology • Vitiligo

Topical Ruxolitinib for Facial Vitiligo: Real-World Experience (EADV 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Dermatology • Immunology • Vitiligo

Topical ruxolitinib in patients with segmental and mixed vitiligo (EADV 2025) - No abstract available

Clinical • Dermatology • Immunology • Vitiligo

An Open-Label, Phase 2, Safety and Efficacy Study of Ruxolitinib Cream in Patients With Genital Vitiligo (EADV 2025) - No abstract available

Clinical • P2 data • Dermatology • Immunology • Vitiligo

Characterization of Vitiligo and Repigmentation Response by Lesion Extent and Distribution: Subgroup Analyses From the Ruxolitinib Cream Phase 2 TRuE-V Mechanism of Action Study (EADV 2025) - No abstract available

P2 data • Dermatology • Immunology • Vitiligo

Ruxolitinib Cream Demonstrated Long-Term Disease Control With Time Off Treatment in Children With Atopic Dermatitis (EADV 2025) - No abstract available

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Efficacy and safety of ruxolitinib cream monotherapy for atopic dermatitis: An updated systematic review and meta-analysis of randomized vehicle-controlled trials with trial sequential analysis (EADV 2025) - No abstract available

Monotherapy • Retrospective data • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Efficacy and Safety of Ruxolitinib Cream Combined With NB-UVB Phototherapy for Treatment of Vitiligo (EADV 2025) - No abstract available

Clinical • Dermatology • Immunology • Vitiligo

Long-Term Safety of Ruxolitinib Cream in Pediatric and Adult Patients: an Analysis of 7 Phase 3 Clinical Trials in Atopic Dermatitis and Nonsegmental Vitiligo (EADV 2025) - No abstract available

Clinical • P3 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics • Vitiligo

Real-world experience insights from Germany and Italy (EADV 2025) - "Sponsored by Incyte. Discuss the practical use of ruxolitinib cream in a real-world setting with insights from Germany and Italy"

Clinical • Real-world • Real-world evidence • Dermatology • Dermatopathology • Immunology • Vitiligo

Latest clinical findings on ruxolitinib cream in vitiligo (EADV 2025) - "Sponsored by Incyte. Understand the latest ruxolitinib cream clinical data from studies on genital involvement and combination treatment with phototherapy"

Clinical • Dermatology • Immunology • Vitiligo

Hub 1.14 Two years on: How ruxolitinib cream is shaping the practical management of vitiligo (EADV 2025) - "Sponsored by Incyte. (Ruxolitinib cream for the management of vitiligo)"

Dermatology • Immunology • Vitiligo

Development of Multiple Flat Warts During Treatment With Ruxolitinib 1.5% Cream for Non-Segmental Vitiligo: A Case Report. (PubMed, Int J Dermatol) - No abstract available

Journal • Dermatology • Immunology • Vitiligo

Topical Ruxolitinib is More Effective at Itch Reduction than Topical Roflumilast in Atopic Dermatitis: A Comparative Meta-Analysis. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

Localized Morphea in a Pediatric Patient Successfully Treated With Topical Ruxolitinib. (PubMed, Pediatr Dermatol) - "Literature on the treatment of localized recalcitrant disease is sparse. We report a case of biopsy-confirmed morphea in a 17-year-old female that significantly improved with topical ruxolitinib 1.5% cream and intralesional triamcinolone after treatment with clobetasol ointment failed."

Journal • Dermatology • Fibrosis • Immunology • Pediatrics • Rare Diseases • Scleroderma • Systemic Sclerosis

Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Incyte Corporation

New P1 trial • Dermatology • Hidradenitis Suppurativa • Immunology

Therapeutic Pipeline (CDA 2025) - "New therapeutics in AD (OX40, Nemolizumab, Delgocitinib, and APG777) 2. New therapeutics in PN (Ruxolitinib) 3. New therapeutics in PsO (Icotrokinra) 4. New therapeutics in HS (Bimekizumab) 5. New therapeutics in CSU (Dupilumab)"

Dermatology

New Treatments in Atopic Dermatitis Update. (PubMed, Ann Allergy Asthma Immunol) - "Non-steroidal topical treatments, such as roflumilast and tapinarof creams, are approved for adults and children down to 6 and 2 years, respectively. Topical Janus kinase (JAK) inhibitors, including ruxolitinib, leverage inhibition of the JAK1 pathway with low concern for toxicity. The use of biologics targeting the interleukin (IL)-4/IL-13 pathway has expanded; dupilumab is approved for patients 6 months and older and tralokinumab and lebrikizumab are approved for 12 years and above. Most recently, nemolizumab, targeting the IL-31 receptor, which mediates nonhistaminergic itch, has been approved for those 12 years and above. Although baricitinib is approved in Europe and Japan, upadacitinib and abrocitinib remain the only oral JAK inhibitors approved for U.S. patients 12 years and older...These innovations represent a shift toward personalized AD management. As the treatment landscape evolves, ongoing research is essential to assess long-term safety and efficacy, as..."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics • IL13 • JAK1 • TNFSF4

Acute and chronic graft-versus-host disease treatment and management in the Eastern Mediterranean region: A Worldwide Network for Blood and Marrow Transplantation survey. (PubMed, Hematol Oncol Stem Cell Ther) - "Our results demonstrated that GvHD management practices in the EM region generally align with current guidelines. However, the results highlight that access to clinical trials and multidisciplinary support teams remains limited."

Journal • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Transplantation